Description
Insmed: Initiation of Coverage – It Is Not Just An ARIKAYCE Story Anymore — Here’s Why BRINSUPRI Matters!
Insmed Incorporated reported financial and operational results for the first quarter of 2026, showing notable progress in both its commercial and clinical programs. Commercially, the company highlighted the continued strong performance of BRINSUPRI, which achieved 44% sequential growth despite Q1 typically being a slower quarter for pharmaceutical sales due to plan changes and reauthorization factors. BRINSUPRI’s launch is described as surpassing historic specialty respiratory product launches, supported by a solid increase in organic demand following the initial patient surge at launch. The company estimates that, having treated nearly all “ready and waiting” patients by the end of Q1, ongoing growth will be driven by a steadily expanding organic demand. Payer approval rates remained favorable, with about 90% authorization and swift turnaround times averaging less than one week. Patient engagement is strong, with over 80% of BRINSUPRI users enrolling in the company’s support program and refill rates exceeding industry benchmarks, contributing to continuation rates that slightly outpace those typical for oral therapies.
